$0.11 Earnings Per Share Expected for Akorn, Inc. (AKRX) This Quarter
Analysts expect that Akorn, Inc. (NASDAQ:AKRX) will announce $0.11 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Akorn’s earnings, with the lowest EPS estimate coming in at $0.07 and the highest estimate coming in at $0.15. The company is scheduled to report its next earnings report on Monday, January 1st.
On average, analysts expect that Akorn will report full year earnings of $0.51 per share for the current financial year, with EPS estimates ranging from $0.49 to $0.52. For the next financial year, analysts anticipate that the company will post earnings of $0.45 per share, with EPS estimates ranging from $0.29 to $0.60. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Akorn.
Akorn (NASDAQ:AKRX) last issued its earnings results on Wednesday, August 1st. The company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by ($0.14). Akorn had a negative return on equity of 12.84% and a negative net margin of 24.21%. The company had revenue of $190.94 million during the quarter, compared to analysts’ expectations of $187.40 million.
Shares of NASDAQ AKRX traded up $0.22 on Wednesday, hitting $13.06. The company had a trading volume of 1,861,800 shares, compared to its average volume of 2,459,526. Akorn has a 12-month low of $10.76 and a 12-month high of $33.63. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.94 and a quick ratio of 2.87. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of 8.08, a PEG ratio of 1.55 and a beta of 1.92.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in Akorn by 30.6% in the second quarter. BlackRock Inc. now owns 10,731,745 shares of the company’s stock valued at $178,040,000 after purchasing an additional 2,515,409 shares during the last quarter. Marshall Wace LLP boosted its holdings in Akorn by 250.5% in the second quarter. Marshall Wace LLP now owns 2,069,385 shares of the company’s stock valued at $34,331,000 after purchasing an additional 1,478,959 shares during the last quarter. Paulson & CO. Inc. purchased a new position in Akorn in the second quarter valued at about $29,198,000. Natixis boosted its holdings in Akorn by 31.3% in the second quarter. Natixis now owns 1,500,471 shares of the company’s stock valued at $24,893,000 after purchasing an additional 357,981 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Akorn by 75.7% in the second quarter. Northern Trust Corp now owns 1,409,291 shares of the company’s stock valued at $23,379,000 after purchasing an additional 607,101 shares during the last quarter. 69.81% of the stock is owned by hedge funds and other institutional investors.
Akorn Company Profile
Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.